A cell-based screen for drugs to treat Huntington's disease.
about
Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregationLarge-scale microfluidics providing high-resolution and high-throughput screening of Caenorhabditis elegans poly-glutamine aggregation model.Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and releaseImprovement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.Green to red photoconversion of GFP for protein tracking in vivo.Inhibitors of cytochrome c release with therapeutic potential for Huntington's diseaseHigh throughput screening for neurodegeneration and complex disease phenotypes.Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's diseaseComposite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions.Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins.Laquinimod treatment in the R6/2 mouse model.Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids.D-β-hydroxybutyrate is protective in mouse models of Huntington's disease.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions.Therapeutic approaches to preventing cell death in Huntington diseaseERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease.Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective.High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model.A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation.Flanking sequences profoundly alter polyglutamine toxicity in yeast.Structural Elucidation of a Small Molecule Inhibitor of Protein Disulfide Isomerase.Phenotypic screens as a renewed approach for drug discovery.Exploring biology with small organic molecules.Development of novel therapies for Huntington's disease: hope and challenge.Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer.Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin.Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and propertiesCannabinoids and Dementia: A Review of Clinical and Preclinical Data.Novel therapeutic targets for Huntington's disease.Strategic approaches to developing drug treatments for ALS.Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response.Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse modelsNeurobiological applications of small molecule screening.Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.Polyglutamine misfolding in yeast: toxic and protective aggregation.Molecular biomarkers of lung carcinoma.Choosing and using Drosophila models to characterize modifiers of Huntington's disease.An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity
P2860
Q24799882-A1B67B46-F0D5-4374-9AA7-B1688DAE6CC1Q28554683-5720CD0E-AD84-4D37-9734-A1D280116C26Q28569078-7DF718BF-E512-4FF5-AF43-8BE5956C5CCBQ30426968-1AB46E3D-B85A-4541-A0BA-0FA48815D83DQ30656864-4C290FEC-3C1A-46B9-8AA2-63CD300403A6Q30847955-14EA6AF8-53AA-4D51-A5E9-5E13E52A9C75Q33323473-675E9EB1-7431-499E-8F0A-74DBCF7E4719Q33327216-284A1952-C5AF-4AF1-87E0-FF424DDB33FDQ33617333-AC9E1C5A-9BCC-4DF6-B22E-016F01966C96Q33747446-D3E89B25-FA46-458E-8DCC-1114B311C64EQ33890346-E384D397-6755-4BE6-9353-38557B094126Q33914305-00088DB1-8691-4800-A5A6-7D3FA6FA0A07Q34023773-FDE1535E-ECF0-436D-A3A1-E143B44F419CQ34066654-BC377996-239B-4511-827E-8117744F3023Q34098292-6F81B24B-CCE2-4620-B287-FF6D84B99C4AQ34392217-4D86E7DE-E934-4F59-A9A2-D6C29D9B1094Q34411338-244A8CAE-CBE8-4391-977E-34C193F21669Q34424253-55EB7509-2EC9-4547-8B56-7F617F2BBA24Q34470561-FB3627C5-9237-4C27-B3AE-511AB41FD9A6Q34560746-26F9C9C6-E6B1-4280-AF21-C6D9839AA1B3Q34657321-6166CC19-11E5-4231-9ABF-A82D043AA6E9Q34984292-9D4AC32D-551C-4066-A845-C1A3A539A176Q35821021-85338974-AA4F-4599-B205-BB8ACC977A12Q35936197-E1A556B0-9E88-437B-888C-3750E1F24E4DQ35986043-5D883BBB-2A2F-40D0-B262-0CABA5CF1B90Q36016932-2A13CE74-5B3A-4966-A9C4-0972D800236BQ36043574-AD1870BB-2D48-4456-816F-48D9AD492A3AQ36080317-FC4B9786-62DF-4D80-9E4D-89D62DC56C6AQ36088674-61E18EDA-F00E-4DD1-934E-10D837FCFF85Q36155898-3A899EBA-D73F-44C1-BEE7-F648176817ECQ36219680-658BB656-E6EB-4BE8-B7A6-FD527102CBAAQ36485321-5FD8A121-796C-4468-9C82-28FCD5AA7A25Q36488831-F9E16F3F-746F-4445-8BA3-B760AE9FF5C0Q37112122-9D6A8141-B87B-4B03-9643-4A7E223ACB96Q37151213-A10F699D-A39E-43FD-90E1-B013B9D2CD10Q37253331-E2701D53-9C64-48ED-A808-490FBF91F4A4Q37952579-E3C287CE-21FE-4B5E-AA31-4B7C394F326FQ37971659-BA4B0F09-F68B-446E-B7AC-C14C067A3A5BQ38027948-F9D5164A-0745-48EC-B832-67EAC86933E1Q38038981-3E616BD9-DCA2-4FDA-B704-438D26F3055F
P2860
A cell-based screen for drugs to treat Huntington's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A cell-based screen for drugs to treat Huntington's disease.
@ast
A cell-based screen for drugs to treat Huntington's disease.
@en
type
label
A cell-based screen for drugs to treat Huntington's disease.
@ast
A cell-based screen for drugs to treat Huntington's disease.
@en
prefLabel
A cell-based screen for drugs to treat Huntington's disease.
@ast
A cell-based screen for drugs to treat Huntington's disease.
@en
P2093
P1476
A cell-based screen for drugs to treat Huntington's disease.
@en
P2093
Allan J Tobin
Charity T Aiken
Erik S Schweitzer
P304
P356
10.1016/J.NBD.2004.04.001
P577
2004-08-01T00:00:00Z